<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365729">
  <stage>Registered</stage>
  <submitdate>3/02/2014</submitdate>
  <approvaldate>11/02/2014</approvaldate>
  <actrnumber>ACTRN12614000171617</actrnumber>
  <trial_identification>
    <studytitle>A phase 1 study of dendrimer-docetaxel (DEP(TM) Docetaxel) in patients with advanced cancer.</studytitle>
    <scientifictitle>A phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) in patients with advanced solid tumours.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Any cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>DEP(TM) Docetaxel (DTX-SPL8783) / Escalating doses by intravenous infusion, single dose once every cycle (cycle length of 3 weeks). Number of doses (i.e., cycles) and dosage amounts will depend on any toxicities occurring at each dose level. Starting dose of 10mg/m2, increased by 1.4 to 2 times at each dose level. Treatment will be continued until tumour progression, unacceptable toxicity or withdrawal from the study based on investigator discretion or patient decision.</interventions>
    <comparator>None - Dose escalation</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determination of the maximum tolerated dose (MTD) as assessed by occurrence of dose limiting toxicities (DLT)</outcome>
      <timepoint>During the first cycle of treatment (i.e. the first 3 weeks of treatment)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>General safety and tolerability profile, as determined by adverse events (AE) including ascites, pericardial effusions or pleural effusions. NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilised for AE assessment and reporting.</outcome>
      <timepoint>Assessed at the end of each cycle of treatment (i.e., every 3 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumour response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria</outcome>
      <timepoint>Screening, and the end of Cycles 3, 6, 9 etc., while on study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile tested via blood assay.</outcome>
      <timepoint>Cycle 1 Days 1, 8 and 15, Cycle 2 Day 1</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with histologically or cytologically confirmed advanced or metastatic cancer for which no standard or curative therapy exists; life expectancy of greater than 12 weeks;	measurable or evaluable disease by RECIST.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy to docetaxel or other components of study therapy or compounds of similar chemical composition; uncontrolled intercurrent illness; participation in a study of an investigational agent within 30 days prior to first study therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>12/02/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>4006 - Herston</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>2170 - Liverpool</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Starpharma Pty Ltd</primarysponsorname>
    <primarysponsoraddress>4-6 Southampton Crescent, Abbotsford, Victoria 3067</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Starpharma Pty Ltd</fundingname>
      <fundingaddress>4-6 Southampton Crescent, Abbotsford, Victoria 3067</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is evaluating the safety, tolerability and pharmacokinetics of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) in patients with advanced solid tumours.

Who is it for? 

You may be eligible to join this study if you are aged over 18 years, have a histologically or cytologically confirmed advanced or metastatic cancer for which no standard or curative therapy exists, a life expectancy greater than 12 weeks, and your disease is measurable or evaluable by the Response Evaluation Criteria In Solid Tumours (RECIST). 

Trial details:

Participants in this study will be administered DEP(TM) Docetaxel (DTX-SPL8783) via intravenous infusion in escalating doses once every 3 weeks. The number of doses and dosage amounts administered to participants are dependent on any toxicities occurring at each dose level. The starting dose is 10mg/m2, increased by 1.4  2 times at each dose level. Treatment will be continued until tumour progression, unacceptable toxicity or withdrawal from the study based on investigator discretion or patient decision.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Health Human Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/01/2014</ethicapprovaldate>
      <hrec>556/13</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research
Level 8, Harold Strokes Building 
Austin Health
145 Studley Road
Heidelberg Victoria 3084</ethicaddress>
      <ethicapprovaldate>22/05/2014</ethicapprovaldate>
      <hrec>HREC-14/Austin/108</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter</name>
      <address>Nucleus Network
5th Floor, Burnet Tower, AMREP Precinct
89 Commercial Rd, Melbourne, Victoria 3004</address>
      <phone>+61 3 90768900</phone>
      <fax />
      <email>j.lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jeremy Paull</name>
      <address>Starpharma Pty Ltd
4-6 Southampton Crescent, Abbotsford, Victoria 3067</address>
      <phone>+61 3 85322736</phone>
      <fax />
      <email>jeremy.paull@starpharma.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jeremy Paull</name>
      <address>Starpharma Pty Ltd
4-6 Southampton Crescent, Abbotsford, Victoria 3067</address>
      <phone>+61 3 85322736</phone>
      <fax />
      <email>jeremy.paull@starpharma.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jeremy Paull</name>
      <address>Starpharma Pty Ltd
4-6 Southampton Crescent, Abbotsford, Victoria 3067</address>
      <phone>+61 3 85322736</phone>
      <fax />
      <email>jeremy.paull@starpharma.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>